RVPH

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Cupertino, California. The company went public in October 2018 and focuses on discovering, developing, and commercializing next-generation therapeutics for diseases with significant unmet medical needs. Reviva operates in the biotechnology sector, specifically targeting central nervous system disorders, respiratory diseases, cardiovascular conditions, metabolic disorders, and inflammatory diseases. As a clinical-stage company, Reviva has not yet brought any products to market and currently generates no revenue while advancing its drug candidates through various phases of clinical trials.